Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
A growing body of evidence supports the hypothesis that the pathophysiology of seborrhoeic
dermatitis has a potentially causative neurogenic inflammatory aspect. ASF1057 is a new drug
that acts through a modulation of neurogenic inflammation through important complementary
mechanisms of action. This study will test the efficacy and safety of ASF1057 in the
treatment of patients with seborrhoeic dermatitis.